Recursion Pharmaceuticals, Inc. (RXRX)
3.53
+0.12
(+3.52%)
USD |
NASDAQ |
Feb 24, 16:00
3.89
+0.36
(+10.20%)
Pre-Market: 09:20
Recursion Pharmaceuticals Research and Development Expense (Quarterly) : 107.66M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Hims & Hers Health, Inc. | 40.96M |
| Intellia Therapeutics, Inc. | 92.33M |
| XOMA Royalty Corp. | 0.069M |
| Mirum Pharmaceuticals, Inc. | 42.90M |
| Tango Therapeutics, Inc. | 30.26M |